Ephedrannin A: A potent dual inhibitor of FAK and Src with anticancer effects DOI Open Access
Hien Thi My Ong, Eda Ates, Min‐Jung Kang

et al.

Bulletin of the Korean Chemical Society, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Abstract Cancer is the leading cause of death worldwide, and development effective treatments remains an important challenge. Here, we present ephedrannin A, a compound that exhibits strong anticancer activity against various types cancer including lung, liver, colon, kidney cancer. The has demonstrated its remarkable ability to inhibit cell proliferation invasion similar conferone Y15, known focal adhesion kinase (FAK) inhibitors. Treatment with 10 μM A significantly reduced expression FAK, phosphorylated FAK proto‐oncogene tyrosine‐protein Src, two major signaling proteins involved in progression kidney, lung lines. Furthermore, knockdown experiments targeting Src found no effect on phosphorylation, suggesting FAK/Src complex inhibition main mechanism action A. Co‐targeting promising therapeutic strategy because these play roles promoting proliferation, migration, invasion. By disrupting pathways, could effectively growth metastasis cells. Further investigation necessary elucidate exact molecular mechanisms underlying effects explore possibility clinical development.

Language: Английский

Network-based approach elucidates critical genes in BRCA subtypes and chemotherapy response in triple negative breast cancer DOI Creative Commons
Piyush Agrawal,

Navami Jain,

Vishaka Gopalan

et al.

iScience, Journal Year: 2024, Volume and Issue: 27(5), P. 109752 - 109752

Published: April 16, 2024

Breast cancers (BRCA) exhibit substantial transcriptional heterogeneity, posing a significant clinical challenge. The global changes in disease context, however, are likely mediated by few key genes which reflect etiology better than the differentially expressed (DEGs). We apply our network-based tool PathExt to 1,059 BRCA tumors across 4 subtypes identify mediator each subtype. Compared conventional differential expression analysis, PathExt-identified greater concordance tumors, revealing shared and subtype-specific biological processes; recapitulate BRCA-associated multiple benchmarks, more essential cell lines. Single-cell transcriptomic analysis reveals distribution of types from tumor microenvironment. Application TNBC chemotherapy response dataset identified processes associated with resistance. described putative drugs that target potentially mediating drug

Language: Английский

Citations

4
Predicting current and future distributions of wild medicinal shrubs Ephedra alata Decne (Ephedraceae) under climate change in Tunisia DOI Creative Commons

Andrio Wibowo

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 12, 2025

Abstract Ephedra alata is a common wild medicinal plant species in Tunisia. The ongoing utilization of E. for applications and uses threatened by the changing climate, this can lead to potential decline alata's geographic distribution range In study, we use modeling estimate both current future alata, providing basis suitable habitats across Herein, climate model was based on two representative concentration pathways representing optimistic scenarios (RCP 2.6) pessimistic 8.5) years 2070. mean temperature coldest quarter, seasonality, precipitation driest known as bioclimatic variables, contribute significantly distributions. Under an scenario, ranges remained stable. On contrary, under scenario 2070, governorates Tunisia will decline, with 44.17–95.35%, or change cause disapearance alata. future, only be available western region, where it previously central eastern regions.

Language: Английский

Citations

0
Untargeted metabolomics approach based on UPLC-ESI-QTOF-MS/MS and evaluation of Antioxidant and Cytotoxic Activities of Nepeta deflersiana Schweinf. ex Hedge Supported by Molecular Modeling and ADMET Analysis DOI

Ines El Mannoubi,

Mozaniel Santana de Oliveira,

Seham Hassan Bashir

et al.

Journal of Molecular Structure, Journal Year: 2025, Volume and Issue: 1333, P. 141767 - 141767

Published: Feb. 15, 2025

Language: Английский

Citations

0
Ephedrannin A: A potent dual inhibitor of FAK and Src with anticancer effects DOI Open Access
Hien Thi My Ong, Eda Ates, Min‐Jung Kang

et al.

Bulletin of the Korean Chemical Society, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Abstract Cancer is the leading cause of death worldwide, and development effective treatments remains an important challenge. Here, we present ephedrannin A, a compound that exhibits strong anticancer activity against various types cancer including lung, liver, colon, kidney cancer. The has demonstrated its remarkable ability to inhibit cell proliferation invasion similar conferone Y15, known focal adhesion kinase (FAK) inhibitors. Treatment with 10 μM A significantly reduced expression FAK, phosphorylated FAK proto‐oncogene tyrosine‐protein Src, two major signaling proteins involved in progression kidney, lung lines. Furthermore, knockdown experiments targeting Src found no effect on phosphorylation, suggesting FAK/Src complex inhibition main mechanism action A. Co‐targeting promising therapeutic strategy because these play roles promoting proliferation, migration, invasion. By disrupting pathways, could effectively growth metastasis cells. Further investigation necessary elucidate exact molecular mechanisms underlying effects explore possibility clinical development.

Language: Английский

Citations

0